HAL-MPE1 Safety and Tolerability Study

NCT ID: NCT02991885

Last Updated: 2020-02-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-31
• Study Completion Date: 2019-09-30

Brief Summary

The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.

Detailed Description

At the time of the study there was no effective treatment available for peanut allergy other than avoidance of peanut allergens. There was high unmet medical need for a disease modifying treatment for peanut allergy, especially for peanut allergic children, since this age group is at highest risk of peanut-related anaphylaxis requiring hospitalization. A chemically modified, aluminum hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed. The safety and tolerability of HAL-MPE1 have been established in a First-in-human (FIH) study in adults.

Conditions

Peanut Allergy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

HAL-MPE1

HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract

Group Type: EXPERIMENTAL

HAL-MPE1

Intervention Type: BIOLOGICAL

Weekly subcutaneous administrations of HAL-MPE1

HAL-MPE1 placebo

HAL-MPE1 placebo without modified peanut extract

Group Type: PLACEBO_COMPARATOR

HAL-MPE1 placebo

Intervention Type: DRUG

Weekly subcutaneous administrations of HAL-MPE1 placebo

Interventions

HAL-MPE1

Weekly subcutaneous administrations of HAL-MPE1

Intervention Type: BIOLOGICAL

HAL-MPE1 placebo

Weekly subcutaneous administrations of HAL-MPE1 placebo

Intervention Type: DRUG

Other Intervention Names

Modified peanut extract; Placebo for modified peanut extract

Eligibility Criteria

Inclusion Criteria

• Signed informed consent/assent
• Male or female subjects aged 5- 50 years
• A well-documented medical history of systemic reactions after ingestion of peanut
• Positive serum specific anti-peanut (>5.0 kU/L) and Ara h 2 Immunoglobulin E (IgE)-test (>2.0 kU/L)
• Skin prick test (SPT) to peanut ≥3 mm compared to negative control within the last 2 years
• Forced expiratory volume at first second (FEV1)>80% predicted (adults and adolescents) or Peak expiratory flow(PEF)>80% predicted (children)
• Negative pregnancy test at screening for females of childbearing potential

Females of childbearing age must be using an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of participation in the study. Contraceptive measures considered adequate are:

• hormonal contraceptives such as contraceptive pills, transdermal patches, intrauterine device (IUD), intrauterine system (IUS) implant, or vaginal ring (started - least 4 weeks prior to Investigational Medicinal Product (IMP) administration)
• double barrier methods: e.g. condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent
• surgical sterilization of the female participant (removal of the uterus or ovaries or tubal ligation)
• participants who are postmenopausal (12 consecutive months without a period) for at least 2 years
• male partner sterilization (vasectomy with documentation of azoospermia) prior to the female patient's entry into trial and is the sole sexual partner for that female patient
• sexual abstinence or having no sexual relationship with a man.

Exclusion Criteria

• Subjects with a history of severe anaphylaxis to peanut with the following symptoms: hypotension, neurological compromise (collapse, loss of consciousness or incontinence) after ingestion of peanuts
• Baseline serum tryptase level >20 µg/l
• Known allergy or hypersensitivity to an excipient in the study drug or placebo
• Clinical features of moderate or severe persistent asthma (as guided by the 2007 NHLBI Guidelines and according to the opinion of the investigator)
• Asthma with FEV1<80% predicted (adults, adolescents) or PEF <80% predicted (children)
• Asthma Control Test (ACT) ≤ 19
• Asthma attack/exacerbation within the last 3 months
• Hospitalization due to asthma within the last year
• Two or more courses of oral steroids within the last 6 months
• History of intubation /mechanical ventilation due to allergies or asthma
• Participation in any interventional study with peanut immunotherapy in the last year
• Any specific immunotherapy (SCIT, Sublingual Immunotherapy (SLIT) or OIT) during the study period
• Severe immune disorders (including autoimmune diseases) and/or diseases requiring immunosuppressive drugs
• Presence of chronic urticaria, atopic dermatitis with flare or atopic dermatitis with SCORAD>40
• Active malignancies or any malignant disease within the past 5 years
• Severe (uncontrolled) diseases that could increase the risk for subjects participating in the study, including but not limited to: any severe or unstable lung diseases; endocrine diseases; clinically significant renal or hepatic diseases, renal impairment, haematological disorders; severe ongoing symptomatic allergic diseases
• History of cardiovascular disease, uncontrolled hypertension or arrhythmias
• Diseases with a contraindication for the use of epinephrine (e.g. hyperthyroidism, glaucoma)
• Use of systemic steroids within 4 weeks before start of the study and during the study
• Treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors
• Vaccination within one week before start of therapy or during study unless considered necessary based on the opinion of the investigator.
• Anti-IgE/anti-Tumor Necrosis Factor (TNF)/omalizumab therapy or any biologic immunomodulatory therapy within the 6 months prior to inclusion and during the study
• Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
• For female adolescents and adults of childbearing potential: Pregnancy (test performed at screening), lactation or inadequate contraceptive measures for women of child-bearing age (contraceptive measures considered adequate are: intrauterine devices, hormonal contraceptives, such as contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release, sexual abstinence or having no sexual relationship with a man)
• Alcohol, drug or medication abuse within the past year
• Any clinically significant abnormal laboratory parameter at screening
• Lack or expected lack of cooperation or compliance
• Unable to use the epinephrine pen correctly
• Severe psychiatric, psychological, or neurological disorders
• Subjects who are employees of the sponsor, institution or 1st degree relatives or partners of the investigators

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HAL Allergy

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Wood, MD

Role: PRINCIPAL_INVESTIGATOR

John Hopkins Hospital Unversity-Divison of Pediatric Allergy

Scott Sicherer, MD

Role: PRINCIPAL_INVESTIGATOR

Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai

Edwin Kim, MD

Role: PRINCIPAL_INVESTIGATOR

UNC Rheumatolory Allergy & Immunology Clinic

Locations

John Hopkins Hospital University-Divison of Pediatric Allergy

Baltimore, Maryland, United States

Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai

New York, New York, United States

UNC Rheumatolory Allergy & Immunology Clinic

Chapel Hill, North Carolina, United States

Allergy, Asthma and Immunology Center

Tulsa, Oklahoma, United States

South Texas Allergy & Asthma Medical Professionals (STAAMP)

San Antonio, Texas, United States

Asthma, Inc.

Seattle, Washington, United States

Inflamax Research Limited

Mississauga, Ontario, Canada

Countries

United States; Canada

References

Reyes AJ, Hosein AS, Ramcharan K, Perot S. Anaphylaxis and other allergic reactions to food: a global challenge. BMJ Case Rep. 2020 May 14;13(5):e231425. doi: 10.1136/bcr-2019-231425.

Reference Type: DERIVED

PMID: 32414772 (View on PubMed)

Other Identifiers

HAL-MPE1/0049

Identifier Type: -

Identifier Source: org_study_id